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Abstract 
Context:  There is a lack of accepted consensus on what should constitute 
appropriate quality-of-care indicators for bladder cancer. 
Objective : To evaluate the optimal management of bladder cancer and propose 
quality indicators (QIs). 
Evidence acquisition : A systematic review was performed to identify literature 
on current optimal management and potential quality indicators for both non–
 
muscle-invasive (NMIBC) and muscle-invasive (MIBC) bladder cancer. A panel 
of experts was convened to select a recommended list of QIs. 
Evidence synthesis : For NMIBC, preoperative QIs include tobacco cessation 
counselling and appropriate imaging before initial transurethral resection of 
bladder tumour (TURBT). Intraoperative QIs include administration of antibiotics, 
proper safe conduct of TURBT using a checklist, and performing restaging 
TURBT with biopsy of the prostatic urethra in appropriate cases. Postoperative 
QIs include appropriate receipt of perioperative adjuvant therapy, risk-stratified 
surveillance, and appropriate decision to change therapy when indicated (eg, 
unresponsive to bacillus Calmette-Guerin). For MIBC, preoperative QIs include 
multidisciplinary care, selection for candidates for continent urinary diversion, 
receipt of neoadjuvant cisplatin-based chemotherapy, time to commencing 
radical treatment, consideration of trimodal therapy as a bladder-sparing 
alternative in select patients, preoperative counselling with stoma marking, 
surgical volume of radical cystectomy, and enhanced recovery after surgery 
protocols. Intraoperative QIs include adequacy of lymphadenectomy, blood loss, 
and operative time. Postoperative QIs include prospective standardised 
monitoring of morbidity and mortality, negative surgical margins for pT2 disease, 
appropriate surveillance after primary treatment, and adjuvant cisplatin-based 
chemotherapy in appropriate cases. Participation in clinical trials was highlighted 
as an important component indicating high quality of care. 
Conclusions : We propose a set of QIs for both NMIBC and MIBC based on 
established clinical guidelines and the available literature. Measurement of these 
QIs could aid in improvement and benchmarking of optimal care of bladder 
cancer. 
Patient summary : After a systematic review of existing guidelines and literature, 
a panel of experts has recommended a set of quality indicators that can help 
providers and patients measure and strive towards optimal outcomes for bladder 
cancer care. 
 
 
1. Introduction 
Bladder cancer (BC) is a common malignancy that is managed by most 
urologists and many other medical professionals. It is a heterogeneous disease 
with variable outcomes. Relevant organisations have published guideline 
recommendations regarding the care of patients with BC [1–8]. However, the 
outcomes from BC treatments vary widely [9,10], suggesting that differences 
exist in health care delivery and guideline compliance. Given these findings, 
patient and caregiver surveys report concerns reflecting variations in service 
provision and outcomes [11–13]. There is a lack of consensus regarding 
appropriate quality-of-care indicators for managing BC. 
A quality-of-care indicator should be based upon accepted standard of care 
evidence-based practice. It should be measurable to allow clinicians, 
administrators, and payers to track, report, and improve outcomes. Feedback 
 
using quality indicators should then drive organisational behaviour to improve 
outcomes and may serve as criteria for approval of centres of excellence. Such 
metrics are increasingly recorded in clinical registries, aiming to assist in 
delivering high-quality care while also facilitating patients’ choice and 
reimbursement incentives, and creating novel research datasets [14,15]. For 
example, to support a culture of quality improvement, National Health Service 
Scotland established a steering group to develop quality performance indicators 
as a proxy measure of quality care for BC (see 
http://www.healthcareimprovementscotland.org/our_work/cancer_care_improvem
ent/cancer_qpis/quality_performance_indicators.aspx). Clinical audit data now 
exist for patients diagnosed between April 2014 and March 2017 [16], although it 
is uncertain how these indicators are currently used within the UK. In the USA, 
the Oregon Urology Institute developed electronic clinical quality measures to 
help urologists submit mandated outcome reports, obtain necessary 
reimbursements, and importantly avoid penalties [17]. 
Over the past decade, BC care has seen an increase in the creation of evidence 
through quality research. This has led to more solid understanding of the biology 
and clinical management of BC. Our aim is to systematically review the 
evidence-based practices for the management of both non–muscle-invasive and 
muscle-invasive disease, and to recommend quality indicators. Clinicians, policy 
makers, and payers may consider these to influence better practices for BC 
patients. Patients may also benefit by being better equipped to ensure their own 
high-quality care. 
 
2. Evidence acquisition 
2.1. Materials and methods 
A comprehensive search of the published literature, assessed through a 
publication date of February 2019, was performed using the following query 
terms: ("Urinary Bladder Neoplasms"[Mesh] OR "Bladder malignancy") AND 
("quality indicators" OR "Quality of care”). This yielded a total of 53 peer-
reviewed articles (Fig. 1). Relevant references within each article were also 
evaluated. Seven articles were excluded as they were either not in English or 
judged not relevant to the topic. Additionally, all 1310 references from the 
aforementioned guidelines [1–8] were screened and reviewed. The scope of this 
paper is limited to that of non–muscle-invasive and muscle-invasive disease; 
therefore, literature related to metastatic disease was not evaluated. 
The systematic review of contemporary literature combined with the experience 
of the authors provided the basis for the following recommendations on which 
quality indicators should exist for optimal BC services. We used a structured, 
consensus-driven, modified Delphi method including a combination of e-mails to 
debate proposals based on evidence and expert opinions from the project team 
and agreed to define the following indicators. We used a two-thirds threshold to 
determine consensus. 
 
 
3. Evidence synthesis 
Our proposed quality indicators relate to non–muscle-invasive bladder cancer 
(NMIBC), muscle-invasive bladder cancer (MIBC), as well as general aspects of 
BC management. 
 
3.1. Quality indicators for NMIBC 
3.1.1. Preoperative 
3.1.1.1. Tobacco cessation counselling 
At the time of diagnosis, patients should be counselled to discontinue tobacco 
smoking. Retrospective studies have found that smoking increases the risk of 
tumour recurrence and progression [18,19] and reduced the efficacy of bacillus 
Calmette-Guerin (BCG) immunotherapy [20]. Although the association between 
smoking cessation and cancer-specific or all-cause mortality is less clear [21,22], 
we recommend that clinicians counsel patients for cessation of smoking, given 
the known beneficial effects on non-BC–related outcomes such as preventing 
cardiovascular events and second tobacco-related primary malignancies. 
Preoperative tobacco cessation also reduces anaesthetic complications. 
To drive appropriate care, physicians should be incentivised to include this as 
part of their preoperative management. For example, in the USA, urologists may 
use a separate billing code for up to a 10-min discussion on the importance of 
and practical steps towards tobacco cessation. Counselling can direct patients to 
pharmacotherapy or referral to a tobacco cessation specialist for cognitive 
behavioural therapy. 
 
3.1.1.2. Appropriate counselling 
Treatment and surveillance should be based on patient’s risk of recurrence and 
progression. For patients who are known to have BC and are on follow-up, the 
following will apply. The European Organization for Research and Treatment of 
Cancer Genito-Urinary Cancer Group has developed a scoring system and risk 
tables to predict recurrence and progression in patients with NMIBC depending 
on patient and disease characteristics, including the number and size of tumours, 
recurrence rate, stage, grade, and the presence of concomitant carcinoma in situ 
(CIS) [23,24]. However, the patient cohort used to develop this scoring system 
did not include patients with CIS alone, and the patients did not receive a second 
transurethral resection of bladder tumour (TURBT) or maintenance BCG. 
Another scoring model for patients who received BCG was developed by the 
Club Urológico Español de Tratamiento Oncológico (Spanish Urological 
Oncology Group), which also considers patient age and gender [25]. These 
scoring systems can guide treatment and surveillance protocols, and allow for 
prognostication of patients. 
 
 
3.1.2. Intraoperative 
3.1.2.1. Administration of perioperative antibiotics 
The best evidence (level 2B) on the role of pre-TURBT antibiotics come from two 
historical randomised trials published in 1988 [26] and 1993 [27], consisting of 91 
and 61 patients, respectively, randomising patients to preoperative antibiotics 
compared with placebo. Both trials revealed a nonsignificant decrease in the 
incidence of postoperative bacteriuria with the use of antibiotic prophylaxis. 
Delavierre et al’s [27] trial found a 0% incidence of symptomatic urinary tract 
infections (UTIs) in both arms. Experts have concluded that “there is moderate to 
low-grade evidence suggesting that antibiotic prophylaxis is not necessary in 
TURBT” [28]. Importantly, there were no subgroup analyses according to the 
presence of risk factors for postoperative infection (eg, immune-compromised 
state, tumour size, and length of surgery). The panel for European Association of 
Urology (EAU) guidelines on urologic infections concluded with a weak 
recommendation that it would be appropriate to use antibiotic prophylaxis for 
patients undergoing TURBT who had a high risk of suffering postoperative sepsis. 
A short guide on how best to use antibiotic prophylaxis in urologic procedures 
has been provided [29]. It has also been shown that adherence to EAU 
guidelines on prophylactic antibiotics reduced antibiotic usage without increasing 
the postoperative infection rate and lowered the prevalence of resistant 
uropathogens [30]. 
The best practice policy statement on urologic surgery antimicrobial prophylaxis 
of the American Urological Association (AUA) [31] is to administer perioperative 
antibiotics in an adequate dose based on patient weight within 60 min of the 
surgical incision and discontinuing these 24 h after surgery. Additionally, 
intraoperative redosing should occur after two antibiotic half-lives to ensure 
sufficient antimicrobial serum levels until the incision is closed. The duration of 
TURBT typically does not exceed 2 h. 
The Global Prevalence of Infections in Urology (GPIU) study is currently the only 
study registering health care–associated urogenital tract infections in urology 
patients, in an on-going surveillance protocol that can help deliver data on 
adequate empirical antibiotic therapy in hospitalised urology patients according to 
guideline recommendations [32], and may report data on post-TURBT sepsis in 
the future. 
 
3.1.2.2. Proper conduct of TURBT—adequate and safe 
A systematic approach is necessary during TURBT to achieve the goal of safe 
and complete bladder tumour resection, via either a fractioned or an en bloc 
strategy [33]. A widely accepted surgical principle for TURBT is to achieve 
adequate resection with detrusor muscle identified [33]. The presence of detrusor 
muscle in the specimen is considered a surrogate indicator of resection quality 
and is mandatory (except for TaG1/LG tumours); its absence is associated with a 
significantly higher risk of residual disease, early recurrence, and tumour 
 
understaging [34]. Submitting the base separately to prove no residual disease 
(completeness of TURBT) and/or to confirm the presence of muscle is 
recommended and can avoid cautery artefact. It is also critical to document the 
number, location, and size of bladder tumours, for example, using a bladder 
diagram. The use of a checklist is also recommended [35–37]. 
A properly conducted TURBT should also be safe. The surgeon should aim to 
avoid bladder perforation and repeated interventions for haemostasis. These 
surgical outcomes should be maintained prospectively in an outcome database; 
complications should be categorised using a standard classification scheme such 
as the Clavien-Dindo classification, with specific outcome data collected for the 
rate of perforation and return to the operating room for haemostasis. The use of 
image-guided TURBT with narrow-band imaging or blue light/fluorescence-
guided “photodynamic diagnosis” with 5-aminolevulinic acid or hexyl 
aminolevulinate [38–40] may be considered a future quality indicator if 
conclusively proven to be superior to conventional TURBT. 
 
3.1.2.3. Restaging TURBT 
The indications for re-resection TURBT include (1) incomplete initial TURBT, (2) 
no muscle in specimen from initial TURBT and not Ta low grade, and (3) T1 
tumours. Residual disease after resection of T1 tumours has been seen in up to 
55% of patients [41]. Without restaging TURBT, there is a high likelihood of 
understaging, as muscle-invasive disease is detected by second resection of 
initial T1 tumour in up to 25% of cases, which rises to 45% if there was no 
muscle in the initial resection [42]. 
In a meta-analysis of published trials comprising 3556 patients with T1 tumours, 
61% of patients had residual disease and 15% subsequently were found to 
upstage to T2 disease [43]. Among the subgroup of T1 tumours with muscle 
present, the prevalence of residual disease was 58% and that of understaging 
was 11%. This underscores the necessity of restaging TURBT in T1 disease 
even if muscle was present in the initial TURBT. 
As for the timing for restaging TURBT, as per EAU guidelines, we recommend 
that this should be performed within 2–6 wk of the initial TURBT and should 
include resection of the primary tumour site. This is based on level 3 
retrospective evidence, which demonstrated longer recurrence- and progression-
free survival among those who underwent a second resection performed 14–42 d 
after initial resection compared with that performed 43–90 d after [44]. 
The pathology results of the restaging TURBT reflect the quality of the initial 
TURBT [9,45], and recording it in a prospectively maintained database is critical. 
In summary, our proposed indicators related to the performance of an adequate 
and safe TURBT are as follows: 
1. Percentage of patients with muscle present in specimen from initial 
TURBT (excluding TaLG disease). 
2. Percentage of patients meeting indications who undergo restaging TURBT. 
 
3. Percentage of patients with muscle present in specimen from restaging 
TURBT. 
 
3.1.3. Postoperative 
3.1.3.1. Immediate instillation of intravesical chemotherapy 
Immediate instillation of intravesical chemotherapy (eg, gemcitabine and 
mitomycin C [MMC]) within 24 h of TURBT has been shown to significantly 
reduce 5-yr recurrence rate by 14% (from 59% to 45%) compared with TURBT 
alone [46]. The recent SWOG S0337 study demonstrated a similar reduction in 
4-yr recurrence rates by 12% (from 47% to 35%) [47]. This is due to the 
intravesical chemotherapeutic agent destroying circulating tumour cells after 
TURBT, preventing tumour cell implantation, and chemoablating residual tumour 
cells at the resection site and small overlooked tumours [48,49]. 
There is no recommendation on which chemotherapeutic agent to use since 
MMC, epirubicin, pirarubicin, and gemcitabine have all shown a beneficial effect 
[46,50,51], with no head-to-head randomised comparisons. 
Despite guidelines from various organisations, adoption of this practice is low 
due to logistical reasons and safety concerns. A population-based study of 32 
068 patients who underwent TURBT in over 300 US hospitals showed that only 
53.1% of hospitals used MMC, and at these hospitals, MMC was used in 6.1% of 
procedures [52]. 
Our proposed quality indicator is the percentage of patients who received 
immediate post-TURBT instillation of intravesical chemotherapy, excluding those 
with contraindications (eg, incomplete resection, suspected perforation, and 
significant haematuria). 
 
3.1.3.2. Intravesical BCG utilisation for intermediate- or high-risk NMIBC with 
appropriate duration of maintenance BCG 
Guidelines recommend that the following groups of patients should be offered 
postoperative intravesical induction followed by maintenance BCG therapy to 
reduce the risk of tumour recurrence or progression: 
1. Intermediate-risk disease (not high or low risk as defined by the following: 
primary, solitary, Ta low grade, <3 cm, no CIS). 
2. High-risk disease (newly diagnosed CIS, T1, and high-grade disease). 
 
The duration of maintenance BCG for patients who completely respond to the 6-
wk course of induction BCG depends on their initial risk stratification 
(intermediate risk: 1 yr; high risk: 3 yr). 
Our proposed quality indicator is simply the percentage of intermediate- and 
high-risk NMIBC patients who were counselled and subsequently initiated BCG. 
Given that some patients subsequently are unable to tolerate the local or 
 
systemic symptoms associated with intravesical BCG therapy, which is then 
appropriately discontinued, our proposed indicator does not intend to measure 
the duration or dose of maintenance BCG therapy. The ability to maintain 
patients on BCG after induction is likely reflective of higher-quality care and 
better ability to rescue continued maintenance. 
The dose of BCG should be prioritised as such [53]. Full-strength BCG must be 
offered to high-risk NMIBC, high-grade T1, and CIS patients receiving induction 
therapy. If this was not possible (eg, due to BCG shortage), then these high-risk 
patients can be given a reduced one-half or -third dose, as supported by several 
trials showing similar outcomes [54–56] and a phase 3 trial showing no difference 
in progression or survival rates [57]. 
Additionally, we recommend measuring the initiation of BCG as a quality 
indicator because the duration of maintenance BCG (1 vs 3 yr) is controversial in 
the context of the global supply constraint of BCG [58–60]. We have summarised 
the various intravesical therapeutic options for NMIBC patients in various 
scenarios (Table 1) and suitable alternatives, particularly during BCG shortage. 
A review by Abufaraj et al [58] provided a list of valid strategies. The National 
Comprehensive Cancer Network guidelines for BC version 3.2019 also 
concurred that the priority for BCG treatment should be given to patients with 
high-risk NMIBC (cT1 high grade or CIS) [53]. 
 
3.1.3.3. Appropriate frequency of surveillance based on stage/grade of BC 
For all patients, guidelines recommend cystoscopic surveillance 3 mo after 
TURBT (Table 2). For low-risk patients, if the first post-TURBT surveillance 
cystoscopy is negative, guidelines recommend cystoscopy at 12 mo followed by 
yearly for 5 yr. For intermediate-risk patients, if the first post-TURBT surveillance 
cystoscopy is negative, guidelines recommend cystoscopy at 3–6-mo intervals 
until 5 yr and yearly thereafter. For high-risk patients, if the first post-TURBT 
surveillance cystoscopy is negative, guidelines recommend cystoscopy every 3 
mo for 2 yr, every 6 mo thereafter until 5 yr, and yearly thereafter. Upper tract 
imaging should be performed yearly. 
Our proposed quality indicators are as follows: 
1. Accurate documentation of risk stratification into low-, intermediate-, or 
high-risk disease. 
2. Appropriate intervals between cystoscopic surveillance. 
3. Appropriate assessment of the upper urinary tract for high-risk patients. 
 
As it may be more complicated to track tumour recurrences, its subsequent 
management, incorporating patient preferences and choices, we have decided to 
omit that from our consideration as a suitable quality indicator. 
 
 
3.2. Quality indicators for MIBC 
3.2.1. Preoperative 
3.2.1.1. Administration of perioperative antibiotics 
The aforementioned GPIU study [32] may report data on posturologic surgical 
sepsis in the future. As for the current prevalence of infectious complications 
after cystectomy, it is worth mentioning data from a large population-based study 
of 57 554 patients in the USA from 2003 to 2013, which revealed a 90-d rate of 
11.9% for UTIs and 1.8% for pyelonephritis [61]. This is similar to 2003–2013 
clinical chart review data from 1133 radical cystectomy patients at USC Institute 
of Urology; 151 UTIs were recorded in 123 patients (11%) during the first 90 d 
postoperatively, with 21/123 (17%) having multiple infections and 25 (20%) 
having urosepsis [62]. Another retrospective study has suggested the benefit of 
discharging patients home on antibiotic prophylaxis following a postoperative 
urine culture obtained during hospitalisation, showing significant differences in 
the rates of documented UTIs (12% in the prophylactic antibiotic group vs 36% in 
the no antibiotic group, p < 0.004) and readmission for urosepsis (2% in the 
antibiotic group vs 17% in the no antibiotic group, p = 0.02) [63]. 
The AUA’s best practice policy statement on urologic surgery antimicrobial 
prophylaxis [31] is to administer perioperative antibiotics in an adequate dose 
based on patient weight within 60 min of the surgical incision, and discontinuing 
these 24 h after surgery. Additionally, intraoperative redosing should occur after 
two antibiotic half-lives to ensure sufficient antimicrobial serum levels until the 
incision is closed. This may be interpreted to include open, laparoscopic, or 
robot-assisted urologic surgical procedures. 
We suggest the following quality indicators: (1) timely administration and 
discontinuation of appropriate antibiotics; (2) rates of UTIs; (3) rates of surgical 
skin infections as classified by the National Surgical Quality Improvement 
Program, in accordance with the need for intervention, for example, bedside 
alternative removal of surgical stiches, image-guided drainage of deep infections, 
take-back to operating room for infection-related complications, etc., and should 
be classified according to the Clavien-Dindo classification as per EAU 
recommendation; and (4) rates of readmissions from urosepsis after radical 
cystectomy (Table 3). 
 
3.2.1.2. Evidence of multidisciplinary care 
For any patient with newly diagnosed ≥cT2 MIBC, we advocate for 
multidisciplinary care to consider curative treatment options prior to choosing the 
best approach based on patient’s comorbidity status, tumour characteristics, and 
patient preferences [3]. This will likely improve utilisation of neoadjuvant 
chemotherapy, but also allow for collaborative discussion of bladder-sparing 
options in appropriate candidates. Clinically appropriate candidates may include 
those who desire to retain their bladders and those with significant comorbid 
conditions that preclude them from undergoing major extirpative surgery (ie, 
radical cystectomy). 
 
Given that practice patterns differ widely [64], tracking referral rates to medical or 
radiation oncologists may under-represent utilisation of multidisciplinary care. 
Patients may be discussed at a multidisciplinary urology tumour board meeting 
prior to a referral being initiated. Therefore, we propose to track the percentage 
of patients with newly diagnosed ≥cT2 MIBC who were discussed at a 
multidisciplinary meeting. 
 
3.2.1.3. Receipt of neoadjuvant chemotherapy 
As part of a multidisciplinary approach, eligible patients should be offered 
neoadjuvant cisplatin-based combination chemotherapy prior to radical 
cystectomy. The latest meta-analysis of 15 randomised trials consisting of 3285 
patients demonstrated a significant overall survival benefit with cisplatin-based 
neoadjuvant chemotherapy compared with local treatment alone (hazard ratio 
[HR] 0.87, 95% confidence interval [CI] 0.79–0.96) [65]. Modern 
chemotherapeutic regimens such as gemcitabine/cisplatin have shown similar 
pT0/pT1 rates as the combination of methotrexate, vinblastine, doxorubicin, and 
cisplatin in the most recent retrospective series and meta-analysis [65,66]. 
Despite this, the use of neoadjuvant chemotherapy in patients undergoing radical 
cystectomy is limited, with as few as 17% of patients with T2 or greater disease 
receiving treatment, even at academic centres [67,68]. A National Cancer Data 
Base (NCDB) analysis of patients with no prior malignancy who ultimately 
underwent radical cystectomy for ≥cT2/cN0/cM0 MIBC between 2006 and 2010 
revealed that the use of neoadjuvant chemotherapy has increased from 10.1% in 
2006 to 20.8% in 2010 [69]. This relatively low proportion—despite level 1 
evidence supporting its use—may be due to patient factors (eg, advanced age, 
comorbidity status, cisplatin eligibility), nonclinical factors (eg, lack of insurance, 
lower income), and conflicting real-world retrospective data on its survival benefit 
[70]. It has also been demonstrated that important baseline differences exist 
between patients from the SWOG-8710 trial and those in general urologic 
practice; in a study evaluating the effectiveness of neoadjuvant chemotherapy 
using the NCDB (2004–2012), there was no clear survival advantage. 
To determine quality of care, it will be important to measure and track the 
utilisation of neoadjuvant chemotherapy for clinically eligible ≥cT2 MIBC with 
urothelial cell carcinoma histology. 
 
3.2.1.4. Time from TURBT to radical cystectomy <12 wk in patients proceeding 
directly to surgery 
It is a widely accepted surgical principle to limit the delay from initial TURBT to 
definitive extirpative radical cystectomy to <12 wk, due to the risk of disease 
progression with more advanced pathologic stage and poorer survival outcomes 
[71–74]. If patients are not considered for or have declined neoadjuvant 
chemotherapy, delaying surgery beyond 12 wk is associated with a significant 
risk of nodal metastasis [75]. A recent SEER-Medicare analysis found that similar 
delays in radical cystectomy increased overall mortality, regardless of the use of 
neoadjuvant chemotherapy [76]. 
 
 
3.2.1.5. Utilisation of trimodal therapy as a bladder-sparing alternative for 
appropriate candidates 
As part of a multidisciplinary approach, eligible patients should be offered 
trimodal therapy (TMT) [2,6,8,77]. TMT is a suitable bladder-sparing alternative 
for patients newly diagnosed with cT2-T3 MIBC, in particular those with 
favourable factors such as maximal visibly complete TURBT, absence of 
hydronephrosis, primary urothelial carcinoma [78], unifocal tumours <6 cm in size, 
absence or limited CIS, as well as good bladder and bowel function [79]. After 
multidisciplinary discussion, these patients should be presented the options of 
radical cystectomy versus bladder-sparing TMT [77,80]. Of note, in new trials 
such as the SWOG/NRG 1806 intergroup phase 3 trial (Clinicaltrials.gov 
Identifier: NCT03775265), patients with unilateral hydronephrosis are eligible as 
long as their glomerular filtration rate is >25 ml/min. 
Especially among those in whom radical cystectomy is contraindicated, who 
refuse cystectomy, or who elect bladder preservation after informed decision 
making [81], TMT represents a viable treatment option with curative intent [79,80]. 
Indicators of quality TMT include the following: (1) receiving a repeat maximal 
TURBT by the treating institution, which is safe but ideally visibly complete; (2) 
receipt of concurrent radiosensitising chemotherapy given level 1 evidence (BC 
2001) and receipt of definitive dose radiotherapy (RT; 64–65 Gy with 
conventional fractionation and 55 Gy with moderate hypofractionation); (3) 
treatment assessment response with cystoscopy/rebiopsy; (4) lifelong 
cystoscopic surveillance since NMIBC recurrence can occur in up to 25% of 
patients; and (5) receipt of salvage cystectomy for muscle-invasive recurrences 
and/or if otherwise indicated in cystectomy candidates [79,82,83]. It underscores 
the importance of a multidisciplinary approach. 
On top of the percentage of patients being referred to and seen by a radiation 
oncologist, we recommend tracking the actual utilisation rate of TMT for MIBC in 
appropriate candidates as a quality indicator. The challenge is to identify who 
these appropriate candidates are, which we have listed above. If TMT is pursued, 
the following may be tracked: (1) repeat maximal TURBT prior to chemoradiation, 
(2) utilisation of concurrent radiosensitising chemotherapy, (3) dose of RT, (4) 
complete response rates, (5) frequency of cystoscopic surveillance, and (6) rates 
of salvage cystectomy. 
 
3.2.1.6. Preoperative counselling with stoma marking 
Preoperative education of patients about to undergo major extirpative surgery for 
MIBC is important, particularly since they will be coping without their native 
bladders postoperatively, with either continent or noncontinent urinary diversion. 
The patient’s abdomen should be evaluated, and the optimal site of stoma should 
be marked prior to surgery. This provides an opportunity to select the optimal site, 
reducing postoperative problems such as leakage, peristomal dermatitis, and 
difficulty with self-care. A randomised controlled trial has been found that a 
preoperative standardised stoma education programme improves patients’ ability 
 
to independently change a stoma appliance postoperatively, as measured by the 
Urostomy Education Scale, a reliable tool to evaluate urostomy self-care skills 
after cystectomy [84,85]. Postoperative stoma care is also important for both 
incontinent ileal conduits and continent neobladders [86]. 
We propose measuring and tracking the percentage of patients referred to an 
enterostomal therapist or a specialist urology nurse clinician before radical 
cystectomy as a surrogate quality indicator for adequate preoperative counselling 
with regard to urinary diversion. 
 
3.2.1.7. Surgical volume of radical cystectomy 
Multiple studies have shown the relationship between surgical volumes of major 
complex surgical procedures with improved surgical outcomes [87–89]. This is 
also the case with radical cystectomy. A meta-analysis in 2011 found a 
significant association between high-volume hospitals and lower mortality 
(pooled odds ratio [OR] 0.55, 95% CI 0.44–0.69) [90]. The systematic review also 
identified two studies showing a beneficial effect of surgeon volume on mortality 
(OR 0.55 and 0.64). A recent systematic review has also revealed fewer 
complications among cystectomies performed by higher-volume providers [91]. 
Proponents of centralisation typically cite these volume-outcome studies and 
have even proposed certain volume standards for high-risk surgical procedures, 
for example, the Leapfrog initiative in the USA [92]. Even though the Leapfrog 
volume thresholds do not specifically include radical cystectomy, its beneficial 
effect on radical cystectomy outcomes has been demonstrated, with Leapfrog 
volume status (higher volume) found to be inversely related to mortality (p = 0.03), 
intra- (p = 0.04) and postoperative (p = 0.04) complications, as well as the 
likelihood of blood transfusion (p < 0.001) [93]. A similar effort was seen in the 
UK with the introduction of the “Improving Outcomes Guidance” (IOG) in 2002, 
which recommended that radical surgery for prostate cancer and BC should be 
provided by teams serving populations of >1 million and carrying out a 
cumulative total of ≥50 operations annually. A study evaluated all radical 
cystectomies performed in England from 2003 to 2014 (N = 15 292), and found 
that, compared with the IOG-noncompliant group, the IOG-compliant group had 
improved median survival time (4.07 vs. 5.41 yrs), lower 30-d (2.9% vs 2.1%) 
and 90-d (7.2% vs. 5.2%) mortality rates, shorter length of stay (16 vs 14 d), and 
decreased reintervention rates (33.6% vs 30.0%, all p < 0.01) [94]. 
Since higher surgical volume may be considered a surrogate marker of better 
overall quality of care [89,95–99], we recommend its use as a quality indicator. 
However, the cut-off used may vary regionally, depending on the density of 
available specialists and other demographic factors. 
 
3.2.1.8. Enhanced recovery after surgery protocols/pathways in place 
Radical cystectomy remains a morbid procedure with complication rates as high 
as 67% even in the care of experienced surgeons [100]. Aspects of a patient’s 
perioperative care can be optimised to improve outcomes for such a major and 
complex oncologic surgical procedure. Enhanced recovery pathway principles 
 
that underlie enhanced recovery after surgery protocols extend across pre-, intra-, 
and postoperative phases of an MIBC patient’s surgical care. This includes 
preoperative avoidance of a formal bowel preparation, preoperative use of 
carbohydrate loading to decrease postoperative insulin resistance, judicious 
intraoperative use of fluids and blood transfusion, early mobilisation 
postoperatively, early resumption of normal diet, and optimal postoperative pain 
management centred around avoidance of narcotics [101–104]. 
 
3.2.2. Intraoperative 
3.2.2.1. Adequacy of lymphadenectomy 
Lymph node status is the best surrogate for long-term recurrence-free and 
overall survival after radical cystectomy [105]. A well-performed 
lymphadenectomy is associated with improved local control rates, curative 
potential, and reasonable morbidity profile postoperatively. Numerous studies 
have been performed to evaluate the anatomic extent of pelvic lympadenectomy 
and how nodal metastases are distributed during radical cystectomy. A higher 
number of dissected lymph nodes have been shown to correlate with improved 
survival rates [106]. At minimum, a “standard” lymphadenectomy should be 
performed; this entails removal of all lymphatic tissue around the common iliac, 
internal and external iliac, and obturator packets bilaterally, and is recommended 
as such in all guidelines. 
In terms of the minimum numbers of lymph nodes required, the AUA/Society for 
Urologic Oncology guidelines recommend that at least 12 lymph nodes be 
evaluated [3]. The EAU guidelines refrained from mandating a number, but state 
that “removal of at least 10 lymph nodes has been postulated as sufficient for 
evaluation of lymph node status, as well as being beneficial for overall survival in 
retrospective studies” [107–109]. 
Both surgical and nonsurgical factors can greatly influence nodal counts, and 
these include anatomic extent of the template and the number of packets 
submitted to pathology [110–112]. 
Two phase 3 randomised trial have evaluated the impact of different pelvic 
lympadenectomy templates on survival. The recently published German trial 
(LEA AUO AB 25/02) randomised 401 patients with locally resectable T1G3 or 
T2-T4aM0 urothelial carcinoma of bladder patients to limited (obturator, and 
internal and external iliac nodes) versus extended lymph node dissection (LND; 
standard + deep obturator, common iliac, presacral, paracaval, interaortocaval, 
and para-aortal nodes up to inferior mesenteric artery). Extended LND failed to 
show superiority over limited LND with regard to recurrence-free survival (5-yr 
recurrence-free survival 65% vs 59%; HR 0.84 [95% CI 0.58–1.22]; p = 0.36), 
cancer-specific survival (5-yr cancer-specific survival 76% vs 65%; HR 0.70; p = 
0.10), and overall survival (5-yr overall survival 59% vs 50%; HR 0.78; p = 0.12). 
Clavien grade ≥3 lymphoceles were more frequently reported in the extended 
LND group within 90 d after surgery (8.6% vs 3.4%, p = 0.04) [113]. The other 
trial, SWOG-1011, completed accrual but results are pending (Clinicaltrials.gov 
Identifier: NCT01224665). 
 
On this basis, our recommendation is that patients undergoing radical 
cystectomy should (at least) receive a standard template pelvic 
lymphadenectomy, and we advocate for this to be a quality indicator. 
 
3.2.3. Postoperative 
3.2.3.1. Prospective standardised monitoring of morbidity and mortality 
A critical component of quality surgical care is the existence of an audit-based 
mechanism of tracking postoperative complications in a standardised and 
prospective manner. We recommend using the Clavien-Dindo classification. 
A population-based study of 36 773 radical cystectomies in the USA from 2004 to 
2010 revealed a 90-d mortality rate of 3.7% [114]. Inpatient mortality rate has 
been found to be 1.7% among 10 027 radical cystectomies done from 2008 to 
2013 in the USA [115]. This is comparable with the 30-d mortality rate of 1.58% 
reported among 2537 cystectomies performed from 2014 to 2015 in the UK, as 
reported in an analysis of the British Association of Urological Surgeons’ 
cystectomy audit [116]. We recommend using a 30-d mortality rate after elective 
radical cystectomy of <2% as a quality indicator. 
The mortality rates among older patients aged >80 yr [117,118] would be 
expectedly higher. It has been found that mortality rates in the salvage radical 
cystectomy setting were similar to the primary setting, that is, 2.2% [119]. 
 
3.2.3.2. Negative surgical margins for pT2 disease 
In a meta-analysis of 38 384 BC patients across 36 studies, it was found that 
4354 patients had positive surgical margins (11.3%). Positive surgical margin 
status was found to be significantly associated with poorer recurrence-free, 
cancer-specific, and overall survival [120]. Achieving negative surgical margins is 
a key aim for radical cystectomy, and the rate may reflect surgical practice. High-
volume centres typically report lower margin rates. For example, in the Memorial 
Sloan-Kettering Cancer Center series of 1655 radical cystectomies from 1985 to 
2005, 858 patients (54%) demonstrated organ-confined disease (≤pT2) and all of 
these patients (100%) had negative surgical margins. Of note, positive surgical 
margin status in the perivesical soft tissue was an independent predictor of 
metastatic progression and increases the probability of disease-specific death 
[121]. Pang et al [101] reported similar data from Sheffield. In 455 consecutive 
radical cystectomies, the soft tissue margin rate was 2.4%, of which all were in 
T3–4 cancers (0% rate for T2). Every safe effort with wide excision should be 
undertaken to obtain negative surgical margins during cystectomy, and this 
should be considered a quality indicator at surgery. 
 
3.2.3.3. Offer adjuvant chemotherapy to patients with high-risk disease (≥pT3 
and/or pN+) who did not receive neoadjuvant chemotherapy 
Guidelines strongly recommend adjuvant cisplatin-based combination 
chemotherapy to patients with pT3/4 and//or pN+ disease if no neoadjuvant 
chemotherapy has been given. This rationale is to eradicate micrometastatic 
 
disease. This is based on meta-analyses demonstrating overall survival and 
disease-free survival benefit [122]. Strength of recommendation has been strong 
despite a lack of high-quality level 1 evidence, as trials have generally failed to 
complete accrual. 
Consideration can be given to adjuvant chemotherapy following TMT as well, as 
was standard in most RTOG/NRG trials [6,119,123]. 
 
3.3. Quality indicators for general aspects of BC services 
These quality indicators are not limited to NMIBC or MIBC (Table 4). 
 
3.3.1. Appropriate imaging for patients newly diagnosed with BC 
Diagnosis of a bladder tumour is typically confirmed visually during flexible 
cystoscopy. The next step prior to initial TURBT will be appropriate imaging. 
Guidelines recommend that patients should undergo cross-sectional computed 
tomography (CT) or magnetic resonance imaging (MRI) with a delayed urogram 
phase prior to the initial TURBT. In patients unable to receive either, options 
include noncontrast CT or MRI, grey-scale or contrast-enhanced ultrasonography 
of the kidneys, or retrograde pyelogram. This is to identify metachronous lesions 
in the upper urinary tract, which occurs in 1.8–2.6% of cases [124,125]. 
For systemic staging, we recommend chest imaging with at least plain x-ray. 
When the chest x-ray is equivocal or an abnormality is identified, or in selected 
high-risk patients, a CT thorax is indicated. For selected high-risk patients, 
including high-grade or clinically muscle-invasive cancers, and for those with 
tobacco smoking exposure (past/present), we recommend CT thorax imaging 
(regardless of the stage of cancer) due to the competing risks of lung cancer, 
particularly if patients are undergoing concurrent imaging of the abdomen and 
pelvis. Low-grade NMIBC does not require chest imaging if there is no clinical 
suspicion. We do not recommend routine CT brain or bone scan unless specific 
symptoms (eg, bone pain) or signs (eg, focal neurology deficit) indicate these 
sites as potential metastases, or neuroendocrine variant histology was identified 
[126]. To put it in context, based on a recent Nationwide Inpatient Sample (1998–
2007) retrospective analysis of 7543 patients, the most common metastatic sites 
for BC were lymph nodes (25%), bone (24%), urinary tract (23%), lung (19%), 
liver (18%), and brain (3%) [127]. However, this study is limited by the use of 
claims to identify metastatic site, with expected variability in the use of imaging 
modalities. 
 
3.3.2. Participation in clinical trials 
Clinical trials evaluate how to prevent, detect, or treat disease [128]. For BC, the 
benefits of participating in clinical trials include access to the latest tools for early 
detection of de novo or recurrent bladder tumours, and the most advanced 
therapeutic options and techniques available to best treat BC. There are currently 
148 trials in the USA [129] and 84 in the UK [130]. When a treatment facility can 
 
actively recruit patients for such trials, it reflects well on the variety of options 
available for patients. 
 
3.3.3. Composite scores that have been developed and evaluated so far 
Disease characteristics remain the main determinant of survival, but high-quality 
surgical technique and optimal perioperative care are mandatory to achieve 
survival benefits in patients with favourable pathology. Quality of surgical 
performance has traditionally been linked to survival outcomes. However, 
survival may not always reflect quality of care because adverse outcomes can 
still result from “nonmodifiable” factors, complexity of the procedure, severity of 
pathology, and associated patient comorbidities. Composite measures that 
combine multiple quality indicators into a single score have improved the 
reliability of assessment of performance [131]. Such measures are crucial for 
comparative effectiveness research. 
Currently, there are three composite scores, mainly developed for robot-assisted 
radical cystectomy (RARC), but most aspects apply to open surgery as well. 
These may be considered as suitable quality indicators for MIBC care. 
Cystectomy Assessment and Surgical Evaluation (CASE) evaluates the surgical 
technique for cystectomy in an objective way based on expert consensus on 
what defines surgical proficiency [132]. Eight domains of the CASE included 
pelvic LND, development of the periureteral space, lateral pelvic space, anterior 
rectal space, control of the vascular pedicle, anterior vesical space, control of the 
dorsal venous complex, and apical dissection. 
The Quality Cystectomy Score (QCS) evaluates the global surgical care that 
patients receive with some outcomes that are directly related to surgical 
technique, based on the following criteria: preoperative (administration of 
neoadjuvant chemotherapy), operative (operative time <6.5 h and estimated 
blood loss <500鳥cc), pathologic (negative soft tissue surgical margins and lymph 
node yield ≥20), and postoperative (no high-grade complications, readmission, or 
noncancer-related mortality within 30鳥d). QCS was categorised as follows: one 
star—achieving two or fewer criteria or mortality within 30鳥d; two stars—meeting 
three or four criteria; three stars—meeting five or six criteria; and four stars—
meeting seven or all criteria. A high QCS was found to be significantly associated 
with better recurrence-free, cancer-specific, and overall survival [133]. 
The Pelvic Lymphadenectomy Appropriateness and Completion Evaluation tool 
evaluates the intraoperative completeness and appropriateness of pelvic LND 
following RARC [134]. 
The rates of neoadjuvant chemotherapy, LND, and positive margins for MIBC 
have been evaluated as a composite “Bladder Cancer Quality Score (BC-QS)” 
using data from the NCDB (2004–2014) for 48 341 patients treated at 1200 
facilities [135]. Improved BC-QS performance was significantly associated with 
lower 30-, 90-d, and overall mortality (adjusted OR 0.78 [0.64–0.96], OR 0.84 
[0.72–0.97], HR 0.86 [0.81–0.92]). This is an easy-to-capture metric correlating to 
pertinent short- and long-term survival outcomes, making it an attractive 
validated quality indicator for policymakers and payers to measure hospital 
quality. The Fox-Chase group had evaluated receipt of neoadjuvant 
 
chemotherapy, timely treatment within 3 mo, adequate LND (≥10 nodes), and 
continent urinary diversion as quality indicators, similarly using the NCDB, which 
tended to occur in academic high-volume institutions; however, this was not 
correlated to survival outcomes [98]. 
The above list of quality indicators for BC services has been endorsed by the 
EAU. 
 
4. Conclusions 
In summary, we propose a set of quality indicators for both NMIBC and MIBC 
that are measurable across the pre-, intra-, and postoperative phases of a 
patient’s journey. These quality indicators are based on the latest evidence-
based clinical practice widely accepted in the urologic community. If utilised 
correctly to drive clinician and organisational behaviour, this set of quality 
indicators can be impactful and improve bladder cancer outcomes. 
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Fig. 1 – PRISMA flowchart. 
ASCO = American Society of Clinical Oncology; ASTRO = American 
Society for Radiation Oncology; AUA = American Urological Association; 
EAU = European Association of Urology; ICUD = International Consultation 
on Urologic Diseases; MIBC = muscle-invasive bladder cancer; NCCN = 
National Comprehensive Cancer Network; NICE = National Institute for 
Health and Care Excellence; NMIBC = non –muscle-invasive bladder cancer; 
PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-
Analyses ; SIU = Société Internationale d'Urologie; SUO = Society for 
Urologic Oncology. 
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Table 1  – Post-TURBT intravesical therapeutic options for patients with non –muscle-invasive bladder cancer 
when BCG is available, in shortage, or absent, and for other alterative options  
 
 Recommendation 
when BCG is 
available 
Recommendation 
during BCG 
shortage a 
Recommendation during 
absence of BCG 
Other options 
High-risk disease  
 Induction Full-strength BCG 
 6 once-a-week 
cycles  
 Full-strength 
BCG  6 once-
a-week cycles 
(priority is for 
BCG-naïve 
patients) 
 If not available, 
then consider 
reduced one-
half or one-third 
dose, if 
feasible. 
 
 Intravesical gemcitabine 
[136,137] 
 Intravesical mitomycin 
[138] 
“Patients with high-risk features (i.e., 
high-grade T1 with additional risk 
factors such as concomitant 
carcinoma in situ, lymphovascular 
invasion, prostatic urethral 
involvement or variant histology) who 
are not willing to take any potential 
oncologic risks with alternative 
intravesical agents, should be offered 
initial radical cystectomy, if they are 
surgical candidates.” 
 Maintenance  Full-strength 
BCG with 3 yr 
of maintenance 
(3-weekly 
instillations at 
3, 6, 12, 18, 
24, 30, and 36 
mo) 
 Consider 1/3 
dose BCG and 
limit dose to 1 
yr. 
 Maintenance 
therapy should 
not be given 
 
 Mitomycin b (monthly 
maintenance up to 1 yr) 
 Epirubicin [139,140] 
 Valrubicin [141] 
 Docetaxel [142] 
 Sequential 
gemcitabine/docetaxel 
 Gemcitabine/mitomycin 
 
 
 [143,144] 
Intermediate-risk disease 
 Induction and 
maintenance 
Intravesical BCG 
for 1 yr (6 weekly 
and 3 weekly at 3, 
6, and 12 mo) or 
intravesical 
chemotherapy for 
up to 12 mo 
Patients with 
recurrent/multifocal 
low-grade Ta 
lesions who 
require intravesical 
therapy should 
receive intravesical 
chemotherapy (eg, 
mitomycin, 
gemcitabine, 
epirubicin, or 
docetaxel) instead 
of BCG 
  
Low-risk 
disease 
BCG should not be used. 
BCG = bacillus Calmette-Guerin; NCCN = National Comprehensive Cancer Network; TURBT = transurethral resection of 
bladder tumour. 
a Recommendations from American Urological Association, American Association of Clinical Urologists, Bladder Cancer Advocacy 
Network, Society of Urologic Oncology, the Large Urology Group Practice Association, and the Urology Care Foundation in 2019 
(available at: https://www.auanet.org/practice-resources/bcg-info/bcg-shortage-notice; last accessed 7 May 2019). 
b As per NCCN guidelines for bladder cancer v3.2019, there were two separate meta-analyses of randomised trials showing no 
differences in risk of recurrence between BCG and mitomycin [145], although BCG may show more favourable outcomes from 
maintenance regimens [146]. 
 
Table 2 – Recommended quality indicators for non –muscle invasive bladder cancer (NMIBC) 
 
Aspect of NMIBC care Recommended quality indicator Level of 
evidence 
Grade of 
recommen
dation 
Preoperative    
Counselling At the time of diagnosis, patients 
should be counselled to discontinue 
tobacco smoking 
2 B 
Risk stratification and surveillance counselling for patients 
with NMIBC 
Use of EORTC and CUETO scoring 
systems to risk stratify patients known 
to have NMIBC and on surveillance 
follow-up 
2 B 
Intraoperative    
Antibiotic prophylaxis Administer perioperative antibiotic 
prophylaxis prior to TURBT. 
2 B 
Conduct of TURBT  Percentage of patients with muscle 
present in specimen from initial 
TURBT (excluding TaLG disease) 
 Percentage of patients meeting 
indications who undergo restaging 
TURBT 
 Percentage of patients with muscle 
present in specimen from restaging 
TURBT 
2 B 
Restaging TURBT Restaging TURBT should be 
performed within 2–6 wk of the initial 
TURBT and include resection of 
primary tumour site 
3 B 
Postoperative    
 
Intravesical therapy  Percentage of patients who 
received immediate post-TURBT 
instillation of intravesical 
chemotherapy, excluding those with 
contraindications (eg, incomplete 
resection, suspected perforation, 
significant haematuria)  
 Percentage of intermediate- and 
high-risk NMIBC patients who were 
counselled and subsequently 
initiated BCG 
2 B 
Appropriate frequency of surveillance based on stage/grade 
of bladder cancer 
 Accurate documentation of risk 
stratification into low-, intermediate-
, or high-risk disease  
 Appropriate intervals between 
cystoscopic surveillance  
 Appropriate assessment of the 
upper urinary tract for high-risk 
patients 
 
2 B 
BCG = bacillus Calmette-Guerin; CUETO = Club Urológico Español de Tratamiento Oncológico; EORTC = European 
Organization for Research and Treatment of Cancer; TURBT = transurethral resection of bladder tumour. 
 
 
Table 3 – Recommended quality indicators for muscle-invasive bladder cancer (MIBC) 
 
Aspect of MIBC care Recommended quality indicator Level of 
evidence 
Grade of 
recommen
dation 
Preoperative    
Administration of perioperative antibiotics  Timely administration and 
discontinuation of appropriate 
antibiotics 
 Rates of urinary tract infection 
 Rates of surgical skin infections as 
classified by the National Surgical 
Quality Improvement Program, in 
accordance with the need for 
intervention (eg, bedside alternative 
removal of surgical stiches, image-
guided drainage of deep infections, 
take-back to operating room for 
infection-related complications, etc.) 
and should be classified according 
to the Clavien-Dindo classification 
as per EAU recommendation 
 Rates of readmissions from 
urosepsis after RC 
2 B 
Evidence of multidisciplinary care Percentage of patients with newly 
diagnosed ≥cT2 MIBC who were 
discussed at a multidisciplinary 
meeting 
2 B 
Receipt of neoadjuvant chemotherapy Utilisation of neoadjuvant 
chemotherapy for clinically eligible 
≥cT2 MIBC with urothelial cell 
1 A 
 
carcinoma histology 
Time from TURBT to radical cystectomy <12 wk in patients 
proceeding directly to surgery 
Percentage of newly diagnosed MIBC 
patients, who are eligible/fit for 
cystectomy, who experienced a delay 
of >12 wk from TURBT to radical 
cystectomy 
3 C 
Utilisation of TMT as a bladder-sparing alternative for 
appropriate candidates  
 Percentage of patients being 
referred to and seen by a radiation 
oncologist 
 Actual utilisation rate of TMT for 
MIBC in appropriate candidates 
(see text for suggested criteria for 
appropriate candidates) 
 If TMT is pursued, the following 
may be tracked:  
o Repeat maximal TURBT 
prior to chemoradiation 
o Utilisation of concurrent 
radiosensitising 
chemotherapy a 
o Dose of RT 
o Complete response rates 
o Frequency of cystoscopic 
surveillance 
o Rates of salvage cystectomy 
2 B 
Preoperative counselling with stoma marking Percentage of patients referred to an 
enterostomal therapist or a specialist 
urology nurse clinician before radical 
cystectomy 
2 B 
Surgical volume of radical cystectomy Note: Since higher surgical volume 
may be considered a surrogate marker 
2 B 
 
of better overall quality of care, we 
recommend its use as a quality 
indicator; however, the cut-off used 
may vary regionally, depending on the 
density of available specialists and 
other demographic factors 
ERAS protocols/pathways in place Percentage of patients undergoing 
radical cystectomy who are placed on 
ERAS protocols/pathways 
  
Intraoperative    
Adequacy of lymphadenectomy Percentage of patients undergoing 
radical cystectomy who receive (at 
least) a standard template pelvic 
lymphadenectomy 
  
Postoperative    
Prospective standardised monitoring of morbidity and 
mortality 
30-d mortality rate after elective radical 
cystectomy of <2% 
2 B 
Negative surgical margins for pT2 disease Percentage of patients undergoing 
radical cystectomy who have negative 
soft tissue surgical margins on final 
histopathology 
3 C 
Adjuvant chemotherapy for select high-risk patients Percentage of high-risk disease (≥pT3 
and/or pN+) who did not receive 
neoadjuvant chemotherapy who were 
offered adjuvant chemotherapy 
postoperatively 
2 B 
EAU = European Association of Urology; ERAS = Enhanced recovery after surgery; RC = radical cystectomy; RT = 
radiotherapy; TMT = trimodal therapy; TURBT = transurethral resection of bladder tumour. 
a Utilisation of concurrent radiosensitising chemotherapy is based on level 1 evidence (BC 2001 trial by James et al [82]). 
 
Table 4 – Recommended quality indicators for general aspects of bladder cancer services 
 
General aspects of bladder cancer care Recommended quality indicator Level of 
evidence 
Grade of 
recommen
dation 
Appropriate imaging for patients newly diagnosed with 
bladder cancer 
 Percentage of newly diagnosed 
MIBC patients who obtained chest 
imaging with either chest XR or CT 
thorax  
 Percentage of newly diagnosed 
bladder cancer patients who have 
cross-sectional imaging of upper 
urinary tract (eg, CT, MRI, or US) 
2 B 
Participation in clinical trials Availability of clinical trials to bladder 
cancer patients who are treated at a 
particular healthcare facility  
4 C 
CT = computed tomography; MIBC = muscle-invasive bladder cancer; MRI = magnetic resonance imaging; US = 
ultrasound; XR = x-ray. 
 
 
